Dr. Julie Maltzman is a medical oncologist with broad experience built over 20 years across all phases of drug development. She joined IconOVir in Oct 2022 from a VP, Global Head of GI Cancers and Cancer Immunotherapy role at Roche/Genentech. There, Dr. Maltzman oversaw the successful registration and commercialization of Atezolizumab and Bevacizumab for HCC. She was also responsible in building and developing the prestigious Morpheus Phase Ib platform study for combination drug development. In 2017, she was the Vice President of Clinical Development and Pharmacovigilance at Nektar Therapeutics. Prior to that she spent several years at Gilead helping the company attempt to transition from a virology company to an oncology company overseeing a number of programs including: JAK2 inhibitor, a Matrix Metalloprotease inhibitor, a BET inhibitor, a BTK inhibitor and an PI3K inhibitor. In 2010, she led early development programs for Morphotek aimed at novel targets such as Folate Receptor Alpha, Mesothelin, GMCSF, and Tissue Factor. Earlier in her career she worked at GSK and helped get lapatinib and pazopanib approved for breast cancer and RCC respectively. Dr. Maltzman received her MD from the University of Colorado Health Science Center and completed her internship and residency at the University of Chicago, Pritzker School of Medicine. She trained as a medical oncologist at the University of Pennsylvania from 2000-2003.
Menu